Novavax, Inc.
NVAXNovavax, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 billion, up 64.7% from fiscal 2024.
- Revenue
- −3.05%
- EPS
- n/m
- Free cash flow
- n/m
- Total debt
- +19.3%
Quarter to September 2026, against a year earlier
Follow NVAX
Alert me
Novavax, Inc. (NVAX) Return on invested capital
Novavax, Inc.'s return on invested capital over the twelve months to Sep 30, 2026 was 0.00%, down 0.0 percentage points from fiscal 2025 (0.00%). Over the past ten years it has ranged from −373.8% (fiscal 2016) to 0.00% (fiscal 2025) — the current reading is the highest in ten years. That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 0.00% | 0.00 |
| FY2024 | 0.00% | 0.00 |
| FY2023 | 0.00% | 0.00 |
| FY2022 | 0.00% | 0.00 |
| FY2021 | 0.00% | 141.24 |
| FY2020 | −141.2% | 1.43 |
| FY2019 | −142.7% | 82.51 |
| FY2018 | −225.2% | 126.75 |
| FY2017 | −351.9% | 21.84 |
| FY2016 | −373.8% | (10.46) |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| NBTX Nanobiotix S.A. - Sponsored ADR compare | 0.00% |
| NVAX Novavax, Inc. | 0.00% |
| OCUL Ocular Therapeutix, Inc. compare | 0.00% |
| TSHA Taysha Gene Therapies, Inc. compare | 0.00% |
| GENB Generate Biomedicines, Inc. compare | 0.00% |
| TYRA Tyra Biosciences, Inc. compare | 0.00% |
| NUVB Nuvation Bio Inc. compare | 0.00% |
| MNKD MannKind Corporation compare | −2.58% |
| LBRX LB Pharmaceuticals Inc compare | −686.2% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)